Ildiko Maria Buck

This inventor holds 32 USPTO granted patents and 6 published patent applications, plus 4 CIPO patents and 9 EPO patents, primarily in Pharmaceutical Compounds. Top assignees: Astex Therapeutics Limited, James Black Foundation Limited, Cancer Research Technology Limited. Active years: 1996-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Ildiko Maria Buck. Retrieved from https://idiyas.com/inventor/ildiko-maria-buck

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 32 (Patent Applications = 6)

% Patents Active = 90.6

CIPO Patents = 4 (Patent Applications = 4)

EPO Patents = 9 (Patent Applications = 11)

Average Co-Inventor Count = 8.5

ph-index = 9

Forward Citations = 217(Granted Patents)

Location History:

Cambridge, GB (2015 - 2017)
London, GB (1996 - 2024)

Company Filing History:

17 out of 126

Astex Therapeutics Limited

patents

10 out of 20

James Black Foundation Limited

patents

5 out of 269

Cancer Research Technology Limited

patents

4. 4 out of 846

Otsuka Pharmaceutical Company, Limited

patents

5. 1 out of 10

Otsuka Pharmaceutical

patents

6. 1 out of 320

Taiho Pharmaceutical Company Limited

patents

where one patent can have more than one assignee

Years Active: 1996-2026

Loading Chart...

Areas of Expertise:

Benzolactam Compounds

Protein Kinase Inhibitors

Isoindolinone Inhibitors

MDM2-P53 Interaction

Bicyclic Heterocycles

Therapeutic Uses

Histamine H3 Receptor

Gastrin Receptor Ligands

Cholecystokinin Ligands

Tetrapeptide Derivatives

Substituted Imidazole Derivatives

Bicyclo 2,2,2-Octane Derivatives

32 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12655137 - Benzolactam compounds as protein kinase inhibitors (2026-06-16),

2. 12202828 - Bicyclic heterocycle compounds and their uses in therapy (2025-01-21),

3. 12071429 - Isoindolinone inhibitors of the MDM2-P53 interaction having anticancer activity (2024-08-27),

4. 11939321 - Benzolactam compounds as protein kinase inhibitors (2024-03-26),

5. 11866428 - Bicyclic heterocycle compounds and their uses in therapy (2024-01-09),

6. 11643410 - Bicyclic heterocycle compounds and their uses in therapy (2023-05-09),

7. 11466016 - Pharmaceutical compounds (2022-10-11),

8. 11261171 - Isoindolinone inhibitors of the MDM2-P53 interaction having anticancer activity (2022-03-01),

9. 11225476 - Bicyclic heterocycle compounds and their uses in therapy (2022-01-18),

10. 11001575 - Benzolactam compounds as protein kinase inhibitors (2021-05-11),

11. 10981898 - Isoindolinone inhibitors of the MDM2-p53 interaction having anticancer activity (2021-04-20),

12. 10618895 - Bicyclic heterocycle compounds and their uses in therapy (2020-04-14),

13. 10544132 - Isoindolinone inhibitors of the MDM2-p53 interaction having anticancer activity (2020-01-28),

14. 10526311 - Isoindolinone inhibitors of the MDM2-P53 interaction having anticancer activity (2020-01-07),

15. 10457669 - Benzolactam compounds as protein kinase inhibitors (2019-10-29),

Sure, please provide me with a moment to gather and organize the information about inventor Ildiko Maria Buck for the article you requested.

Profile summary based on public USPTO records.